18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis is a PHASE3 clinical asset sponsored by Azafaros B.V. in Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis. SEO and diligence focus: AZ-3102, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.